234 related articles for article (PubMed ID: 25547492)
1. The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes.
Stiborová M; Černá V; Moserová M; Mrízová I; Arlt VM; Frei E
Int J Mol Sci; 2014 Dec; 16(1):284-306. PubMed ID: 25547492
[TBL] [Abstract][Full Text] [Related]
2. Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5.
Stiborová M; Poljaková J; Martínková E; Ulrichová J; Simánek V; Dvořák Z; Frei E
Toxicology; 2012 Dec; 302(2-3):233-41. PubMed ID: 22917556
[TBL] [Abstract][Full Text] [Related]
3. Application of hepatic cytochrome b
Reed L; Indra R; Mrizova I; Moserova M; Schmeiser HH; Wolf CR; Henderson CJ; Stiborova M; Phillips DH; Arlt VM
Toxicol Appl Pharmacol; 2019 Mar; 366():64-74. PubMed ID: 30685480
[TBL] [Abstract][Full Text] [Related]
4. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases.
Stiborová M; Indra R; Moserová M; Cerná V; Rupertová M; Martínek V; Eckschlager T; Kizek R; Frei E
Chem Res Toxicol; 2012 May; 25(5):1075-85. PubMed ID: 22390216
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome b(5) shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy.
Kotrbová V; Mrázová B; Moserová M; Martínek V; Hodek P; Hudeček J; Frei E; Stiborová M
Biochem Pharmacol; 2011 Sep; 82(6):669-80. PubMed ID: 21683692
[TBL] [Abstract][Full Text] [Related]
7. The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism.
Aimová D; Svobodová L; Kotrbová V; Mrázová B; Hodek P; Hudecek J; Václavíková R; Frei E; Stiborová M
Drug Metab Dispos; 2007 Oct; 35(10):1926-34. PubMed ID: 17656468
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency.
Stiborová M; Rupertová M; Frei E
Biochim Biophys Acta; 2011 Jan; 1814(1):175-85. PubMed ID: 20576524
[TBL] [Abstract][Full Text] [Related]
9. The effect of benzo[a]pyrene on metabolic activation of anticancer drug ellipticine in mice.
Stiborova M; Cerna V; Moserova M; Arlt VM; Frei E
Neuro Endocrinol Lett; 2013; 34 Suppl 2():43-54. PubMed ID: 24362092
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome
Stiborová M; Indra R; Frei E; Kopečková K; Schmeiser HH; Eckschlager T; Adam V; Heger Z; Arlt VM; Martínek V
Monatsh Chem; 2017; 148(11):1983-1991. PubMed ID: 29104319
[TBL] [Abstract][Full Text] [Related]
11. Ellipticine and benzo(a)pyrene increase their own metabolic activation via modulation of expression and enzymatic activity of cytochromes P450 1A1 and 1A2.
Aimová D; Poljaková J; Kotrbová V; Moserová M; Frei E; Arlt VM; Stiborová M
Interdiscip Toxicol; 2008 Sep; 1(2):160-8. PubMed ID: 21218107
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells.
Martinkova E; Dontenwill M; Frei E; Stiborova M
Neuro Endocrinol Lett; 2009; 30 Suppl 1():60-6. PubMed ID: 20027146
[TBL] [Abstract][Full Text] [Related]
13. The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide.
Stiborová M; Sejbal J; Borek-Dohalská L; Aimová D; Poljaková J; Forsterová K; Rupertová M; Wiesner J; Hudecek J; Wiessler M; Frei E
Cancer Res; 2004 Nov; 64(22):8374-80. PubMed ID: 15548707
[TBL] [Abstract][Full Text] [Related]
14. Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes.
Kotrbová V; Aimová D; Brezinová A; Janouchová K; Poljaková J; Frei E; Stiborová M
Neuro Endocrinol Lett; 2006 Dec; 27 Suppl 2():18-22. PubMed ID: 17159771
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.
Kolarik M; Indra R; Adam V; Heger Z; Kopeckova K; Arlt VM; Stiborova M
Neuro Endocrinol Lett; 2019 Feb; 39(7):515-524. PubMed ID: 30860683
[TBL] [Abstract][Full Text] [Related]
16. Antitumor drug ellipticine inhibits the activities of rat hepatic cytochromes P450.
Aimová D; Stiborová M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):437-40. PubMed ID: 16601806
[TBL] [Abstract][Full Text] [Related]
17. Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes.
Frei E; Bieler CA; Arlt VM; Wiessler M; Stiborová M
Biochem Pharmacol; 2002 Jul; 64(2):289-95. PubMed ID: 12123750
[TBL] [Abstract][Full Text] [Related]
18. Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems.
Stiborová M; Borek-Dohalská L; Aimová D; Kotrbová V; Kukacková K; Janouchová K; Rupertová M; Ryslavá H; Hudecek J; Frei E
Gen Physiol Biophys; 2006 Sep; 25(3):245-61. PubMed ID: 17197724
[TBL] [Abstract][Full Text] [Related]
19. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
Poljakova J; Hrebackova J; Dvorakova M; Moserova M; Eckschlager T; Hrabeta J; Göttlicherova M; Kopejtkova B; Frei E; Kizek R; Stiborova M
Neuro Endocrinol Lett; 2011; 32 Suppl 1():101-16. PubMed ID: 22167207
[TBL] [Abstract][Full Text] [Related]
20. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling.
Stiborová M; Breuer A; Aimová D; Stiborová-Rupertová M; Wiessler M; Frei E
Int J Cancer; 2003 Dec; 107(6):885-90. PubMed ID: 14601046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
